Apogee Therapeutics (APGE) Income towards Parent Company (2022 - 2026)

Apogee Therapeutics (APGE) has reported Income towards Parent Company for 5 consecutive years, with -$74.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company fell 33.92% year-over-year to -$74.1 million; the TTM figure through Mar 2026 stood at -$220.7 million (down 7.73% YoY), while the FY2025 annual figure was -$201.9 million, down 11.18% from the prior year.
• Income towards Parent Company eased to -$74.1 million in Q1 2026 per APGE's latest filing, from -$15.4 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$1.8 million in Q2 2022 and bottomed at -$74.1 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$37.9 million across 5 years, with a median of -$33.0 million in 2024.
• Annual changes were most pronounced in 2023 — Income towards Parent Company plunged 939.92% — and 2025, when it jumped 76.84%.
• Apogee Therapeutics' Income towards Parent Company stood at -$20.8 million in 2022, then sank by 197.92% to -$61.9 million in 2023, then decreased by 7.66% to -$66.7 million in 2024, then surged by 76.84% to -$15.4 million in 2025, then plunged by 379.99% to -$74.1 million in 2026.
• Business Quant data shows APGE's Income towards Parent Company at -$74.1 million in Q1 2026, -$15.4 million in Q4 2025, and -$65.0 million in Q3 2025.